125 related articles for article (PubMed ID: 7595555)
1. Suppression of mitochondrial succinate dehydrogenase, a primary target of beta-amyloid, and its derivative racemized at Ser residue.
Kaneko I; Yamada N; Sakuraba Y; Kamenosono M; Tutumi S
J Neurochem; 1995 Dec; 65(6):2585-93. PubMed ID: 7595555
[TBL] [Abstract][Full Text] [Related]
2. Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: conversion of non-toxic [D-Ser(26)]beta-amyloid 1-40 to toxic and proteinase-resistant fragments.
Kaneko I; Morimoto K; Kubo T
Neuroscience; 2001; 104(4):1003-11. PubMed ID: 11457586
[TBL] [Abstract][Full Text] [Related]
3. [Neurotoxicity of beta-amyloid].
Kaneko I; Kubo T; Morimoto K
Nihon Yakurigaku Zasshi; 2000 Feb; 115(2):67-77. PubMed ID: 10876793
[TBL] [Abstract][Full Text] [Related]
4. Amyloid beta protein inhibits cellular MTT reduction not by suppression of mitochondrial succinate dehydrogenase but by acceleration of MTT formazan exocytosis in cultured rat cortical astrocytes.
Abe K; Saito H
Neurosci Res; 1998 Aug; 31(4):295-305. PubMed ID: 9809588
[TBL] [Abstract][Full Text] [Related]
5. Substrate-dependence of reduction of MTT: a tetrazolium dye differs in cultured astroglia and neurons.
Takahashi S; Abe T; Gotoh J; Fukuuchi Y
Neurochem Int; 2002 Apr; 40(5):441-8. PubMed ID: 11821152
[TBL] [Abstract][Full Text] [Related]
6. [Amyloidogenic peptides such as beta-amyloid, amylin and calcitonin strongly enhance the susceptibility of rat hippocampal neurons to excitatory amino acids in vivo].
Morimoto K; Nagata S; Kubo T; Oda T; Kaneko I
Nihon Yakurigaku Zasshi; 1998 Oct; 112 Suppl 1():83P-87P. PubMed ID: 10190140
[TBL] [Abstract][Full Text] [Related]
7. Beta-amyloid (1-42) affects MTT reduction in astrocytes: implications for vesicular trafficking and cell functionality.
Kerokoski P; Soininen H; Pirttilä T
Neurochem Int; 2001 Feb; 38(2):127-34. PubMed ID: 11137881
[TBL] [Abstract][Full Text] [Related]
8. Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer disease.
Kubo T; Kumagae Y; Miller CA; Kaneko I
J Neuropathol Exp Neurol; 2003 Mar; 62(3):248-59. PubMed ID: 12638729
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death.
Shearman MS; Ragan CI; Iversen LL
Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1470-4. PubMed ID: 8108433
[TBL] [Abstract][Full Text] [Related]
10. The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides.
Shearman MS; Hawtin SR; Tailor VJ
J Neurochem; 1995 Jul; 65(1):218-27. PubMed ID: 7790863
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction.
Berridge MV; Tan AS
Arch Biochem Biophys; 1993 Jun; 303(2):474-82. PubMed ID: 8390225
[TBL] [Abstract][Full Text] [Related]
12. A novel compound RS-0466 reverses beta-amyloid-induced cytotoxicity through the Akt signaling pathway in vitro.
Nakagami Y; Nishimura S; Murasugi T; Kubo T; Kaneko I; Meguro M; Marumoto S; Kogen H; Koyama K; Oda T
Eur J Pharmacol; 2002 Dec; 457(1):11-7. PubMed ID: 12460638
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis.
Liu Y; Schubert D
J Neurochem; 1997 Dec; 69(6):2285-93. PubMed ID: 9375659
[TBL] [Abstract][Full Text] [Related]
14. The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology.
Seilheimer B; Bohrmann B; Bondolfi L; Müller F; Stüber D; Döbeli H
J Struct Biol; 1997 Jun; 119(1):59-71. PubMed ID: 9216088
[TBL] [Abstract][Full Text] [Related]
15. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients.
Kubo T; Nishimura S; Kumagae Y; Kaneko I
J Neurosci Res; 2002 Nov; 70(3):474-83. PubMed ID: 12391608
[TBL] [Abstract][Full Text] [Related]
16. Both oxidative stress-dependent and independent effects of amyloid beta protein are detected by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction assay.
Abe K; Saito H
Brain Res; 1999 May; 830(1):146-54. PubMed ID: 10350568
[TBL] [Abstract][Full Text] [Related]
17. Congo red reverses amyloid beta protein-induced cellular stress in astrocytes.
Abe K; Kato M; Saito H
Neurosci Res; 1997 Oct; 29(2):129-34. PubMed ID: 9359461
[TBL] [Abstract][Full Text] [Related]
18. Amyloid beta toxicity consists of a Ca(2+)-independent early phase and a Ca(2+)-dependent late phase.
Abe K; Kimura H
J Neurochem; 1996 Nov; 67(5):2074-8. PubMed ID: 8863516
[TBL] [Abstract][Full Text] [Related]
19. NADH-dependent dehydrogenase activity estimation by flow cytometric analysis of 3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction.
Huet O; Petit JM; Ratinaud MH; Julien R
Cytometry; 1992; 13(5):532-9. PubMed ID: 1633732
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of V-type ATPases, bafilomycin A1 and concanamycin A, protect against beta-amyloid-mediated effects on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction.
Kane MD; Schwarz RD; St Pierre L; Watson MD; Emmerling MR; Boxer PA; Walker GK
J Neurochem; 1999 May; 72(5):1939-47. PubMed ID: 10217271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
